Moderate-to-Severe Ulcerative Colitis: What to Do When Initial Advanced Therapy Falls Short
This protocol addresses adult outpatients with moderate-to-severe ulcerative colitis (Mayo Clinic score 6–12) who are naive to advanced therapies and have had an incomplete response to their first-line advanced treatment — failing to reach the required symptomatic, biochemical, or endoscopic milestones.
Previous line — failure condition
For advanced therapy-naive patients, the recommended first step is early (top-down) initiation of a higher-efficacy agent — infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, or guselkumab — or an intermediate-efficacy agent — golimumab, ustekinumab, tofacitinib, filgotinib, or mirikizumab — with or without an immunomodulator.
Goals not achieved — triggering escalation
Symptomatic response within 3 months; symptomatic and biochemical (clinical) remission within 3–6 months (Mayo Clinic score <3, no individual subscore >1); endoscopic improvement or remission within 6–12 months.
Next step — partial treatment overview
For patients with an incomplete initial response — particularly those with severe disease — an extended induction period or dose escalation of the current agent may be appropriate for certain medications. The complete decision criteria, preferred agents, and full algorithm are available in the structured protocol below.
Clinical goals
✓
Clinical response and clinical remission by end of extended induction — assessed at approximately week 16.
References
DOI: 10.1053/j.gastro.2024.10.001
In adult outpatients with moderate-to-severe UC who are naïve to advanced therapies, the AGA suggests using a HIGHER efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab) OR an INTERMEDIATE efficacy medication (golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab), rather than a LOWER efficacy medication (adalimumab).
Scores of 6–12 correspond to moderate-to-severe disease activity, whereas clinical remission is most consistently defined as Mayo Clinic score <3, with no individual subscore >1.
In patients, particularly those with severe disease, extended induction regimens (for up to 16 wk) or dose escalation upon may be beneficial for certain agents.
Among patients who did not respond to the 10-mg twice daily dose of tofacitinib at week 8 in the OCTAVE trial, 52% achieved clinical response at week 16 after extended induction with 10-mg twice daily dosing for an additional 8 weeks.
Nearly one-half (48%) of patients who failed to respond to the initial 8-week induction regimen with upadacitinib 45 mg/d responded to an additional 8 weeks of induction therapy.
Similarly, an additional 3 IV induction doses of mirikizumab showed benefit in patients with incomplete response to the first 3 weeks’ induction dosing.
View source ↗